Neuronetics STIM 深 沪
等待开盘 07-18 09:30:00 美东时间
3.83
+0.230
+6.39%
华盛通- 最 高3.83
- 今 开3.62
- 成交量 47.05万股
- 最 低 3.56
- 昨 收 3.60
- 总市值 2.52亿
- 52周最高 5.92
- 市盈率 静 --
- 换手率 0.71%
- 52周最低 0.52
- 委 比 -57.54%
- 总股本 6582.03万
- 历史最高 39.39
- 量 比 1.02
- 振 幅 7.50%
- 历史最低 0.52
- 每 手 1
- 风险率 1.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Neuronetics Appoints New CFO Amid Strategic Expansion
Neuronetics ( ($STIM) ) has issued an update. On July 15, 2025, Neuronetics app...
07-15 20:00
Neuronetics Appoints Steven Pfanstiel As CFO, Effective July 15, 2025; Reaffirms Q2, FY25 Guidance Citing Integration Of Greenbrook Operations And Continued Progress Across Key Growth Drivers
Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced succession
07-15 19:33
Neuronetics Appoints New Chief Financial Officer
Neuronetics appoints Steven Pfanstiel as Chief Financial Officer, succeeding Steve Furlong who will retire in March 2026. Pfanstiel, with over 20 years of experience in healthcare, joins Neuronetics to drive growth and profitability, leveraging his expertise in medical technology and pharmaceuticals. The company reaffirms its financial guidance for Q2 and full-year 2025, supported by successful integration of Greenbrook operations.
07-15 11:30
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics, Inc. announced the granting of inducement awards, including PRSUs and RSUs, to Jeff Jones, a new non-executive employee. The PRSU awards are tied to achieving cash flow breakeven in specific fiscal quarters, with different vesting schedules based on performance. The RSUs will vest in three equal installments over three years. Neuronetics focuses on neurohealth treatments, offering non-drug therapies and SPRAVATO® for depression.
06-19 23:00
Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook’s Personalized Care Trial Program
Neuronetics, Inc., a leader in mental health care technology, attends the 13th Annual Clinical TMS Society (CTMSS) Meeting as a Silver Sponsor. The company presents two posters at the event, showcasing real-world outcomes from the TrakStar® database, including analyses of TMS efficacy in elderly adults with depression and a comparison of NeuroStar’s Figure-8 coil with Brainsway’s H-coil. Additionally, Neuronetics participates in the PULSES Course...
06-10 12:31
渤小海伴您读研报之芯动联科
（转自：渤海证券财富管理） 1.公司概况 1.1MEMS惯性传感器国内龙头，研发实力卓越 芯动联科主营业务为高性能硅基MEMS（Micro-Ele...
06-05 09:39
Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes
<p>Neuronetics, Inc. announced its upcoming inclusion in the Russell 3000 and Russell 2000 Indexes, effective June 30, 2025. This marks recognition of the company's strategic vision and operational progress in revolutionizing mental healthcare delivery. Neuronetics, a leader in neurohealth therapies, combines its NeuroStar technology with a growing network of Greenbrook clinics to expand access to innovative treatments. The inclusion enhances vis...
06-02 20:30
ElectroCore anticipates $30M 2025 revenue amid product line expansion
Earnings Call Insights: electroCore (ECOR) Q1 2025 Management View CEO Dan Goldberger emphasized the company's transformation into a broader bioelectronic technology entity, highlighting the recent ac...
05-08 11:18
Neuronetics Reports Updated Q4 Results; Net Loss $(0.33)
Fourth Quarter 2024 Results for the Three Months Ended December 31, 2024a $0.6 million reduction in the 2024 bonus accrual that the Company assumed in connection with its acquisition of Greenbrook, resulting in an
03-28 04:38
美股大行评级 | 摩根大通：维持Alignment Healthcare"中性"评级，目标价从14美元升至17美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1104689832132448256.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Chardan Capital：维持Ocugen(OCGN)"买入"评级，目标价从6美元升至7美元</p> <p>• Piper Sandler：维持ALX Oncology Holdings(ALXO)"超配"评级，目标
03-07 13:53
